Daniel Isenbarger, MD
Cardiovascular Disease · Hillsboro, ORNPI 1780765941
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Abbott at 50.9% of the total. Reporting peaked in 2019 at $3,414 and has fallen 89.1% since, to $371 in 2025.
Across 105 payments — averaging $80.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Abiomed$612
- Cardiovascular Systems Inc.$437
- Boston Scientific$254
- Philips North America LLC$143
- plus $768 from 17 others
What the payments were for
- Consulting fees$1181%
- Travel & lodging$3,72744%
- Food & beverage$4,58454%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $4,301 |
| Medtronic(2 entities) | 14 | $1,929 |
| Abiomed | 13 | $612 |
| Cardiovascular Systems Inc. | 4 | $437 |
| Boston Scientific | 5 | $254 |
| Philips North America LLC | 4 | $143 |
| Shockwave Medical, Inc | 3 | $140 |
| Penumbra, Inc. | 4 | $74 |
| Chiesi USA, Inc. | 3 | $64 |
| AstraZeneca | 4 | $62 |
| Cordis US CORP. | 3 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $60 |
| Boehringer Ingelheim | 2 | $49 |
| Inari Medical, Inc. | 2 | $44 |
| Pfizer | 2 | $44 |
| Recor Medical Inc | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Bayer | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,935
- HawkOne$1,592
- Omnilink Elite vascular stent system$1,213
- Diamondback Peripheral$560
- MitraClip System$169
- COROFLOW$101
How this compares
$8,443 in reported general payments places this provider in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $97,846 |
| EntrestoSacubitril/Valsartan | 49 | $66,634 |
| JardianceEmpagliflozin | 43 | $59,721 |
| Repatha SureclickEvolocumab | 42 | $57,605 |
| XareltoRivaroxaban | 24 | $38,620 |
| FarxigaDapagliflozin Propanediol | 34 | $34,514 |
| Metoprolol Succinate | 218 | $2,759 |
| ClopidogrelClopidogrel Bisulfate | 159 | $2,232 |
| Eplerenone | 19 | $2,160 |
| Rosuvastatin Calcium | 109 | $2,106 |
| Atorvastatin Calcium | 105 | $1,331 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $1,059 |
| Propranolol Hcl | 14 | $846 |
| Losartan Potassium | 72 | $832 |
| Amlodipine Besylate | 75 | $819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $97,84676 claims |
| Boehringer IngelheimJardiance | $49 | $59,72143 claims |
| AstraZenecaFarxiga | $62 | $34,51434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Hillsboro
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.